Atrial Fibrillation, Stroke, Ischemic, Transient Ischemic Attack
Conditions
Keywords
Autonomic Dysfunction, Inflammation, Cognitive impairment, Interoception, Gait impairment
Brief summary
This prospective non-interventional cohort study investigates the pathophysiology of Atrial Fibrillation Detected After Stroke or transient ischemic attack (AFDAS) by comparing the autonomic function and inflammation between patients with AFDAS, patients with atrial fibrillation (AF) diagnosed before the ischemic event or known AF (KAF), and patients with normal sinus rhythm (NSR) after 14 day of cardiac monitoring following the event onset.
Detailed description
This study enrolls patients with acute ischemic stroke at the London Health Sciences Center in London, Ontario, Canada. The heart rhythm of the patients is monitored with a CardioSTAT® Holter device (Icentia) for 14 days after the ischemic event onset. Based on this cardiac monitoring and previous medical history, patients are stratified into three groups: (a) atrial fibrillation detected after stroke or transient ischemic attack (AFDAS), (b) atrial fibrillation diagnosed before the ischemic event or known AF (KAF), and (c) normal sinus rhythm (NSR). Autonomic function is assessed by the levels of plasma catecholamines, a battery of validated autonomic tests \[autonomic reflex screening (ARS)\], heart rate variability (HRV) through data obtained by Holter monitoring by standard quantitative analysis methods according to the guidelines of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology and by the analysis of diurnal variation of heart rate. Blood samples are collected for the analysis of inflammatory markers (e.g. CRP, TNF-α, IL-1β, and IL-6), and potential AFDAS predictors such as brain natriuretic peptide (BNP- AFDAS biomarker), endothelin-1 (endothelial dysfunction marker), Lipoprotein(a) \[Lp(a)\] and thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels, TAFI activity, TAFI single nucleotide polymorphisms (SNPs), apo(a) isoform size and plasma catecholamines levels. Furthermore, specific neuroimaging findings (e.g., specific regions of the insula or its connections) and clinical features (e.g., impaired interoceptive processing, cognitive impairment, etc) are also analyzed. Interoception is assessed using a heartbeat detection task without feedback condition and gait, balance, frailty, and cognitive status in patients are evaluated by the administration of a battery of tests. Stroke recurrence will be assessed by a structured phone interview at 6 and 12 months after the initial stroke.
Interventions
None listed
Sponsors
Western University, Canada
London Health Sciences Centre
Parkwood Hospital, London, Ontario
El Instituto de Neurociencia Cognitiva y Traslacional (INCYT)
Instituto de Neurologia Cognitiva (INECO)
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. MCA territory-transient ischemic attack or -acute ischemic stroke patients seen in the Emergency Department or admitted to University Hospital, London, Ontario, Canada 2. Age ≥ 18 years old 3. Patient or Substitute Decision Maker must give written informed consent
Exclusion criteria
1. Patients with autonomic dysfunction such as Parkinson's disease that can be interfering with outcome assessment based on qualified investigator's judgment. 2. Patients taking tricyclic antidepressant (TCAs) 3. Patients in whom the acute stroke is primarily hemorrhagic 4. Patients with both TIA and atrial fibrillation 5. Patients with both TIA and large vessel disease 6. Patients with inflammatory diseases
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes and Differences in Inflammatory Responses | Within 48 hours of stroke onset and at 12, 30 and 90 days. | Differences in levels of plasma markers or temporal responses (CRP,TNFα, IL-6, IL-1β, etc) between patients with (a) AFDAS, (b)KAF and (c) NSR. |
| Changes and Differences in Heart Rate Variability (HRV) | At 14 days. | Differences in HRV parameters between patients with (a) AFDAS, and (b) NSR |
| Changes and Differences in Autonomic Function | Within 48 hours of stroke onset and at 12, 30 and 90 days. | Differences in Composite Autonomic Severity Score (CASS) on an 11-point scale between patients with (a) AFDAS, (b) KAF , and (c) NSR |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Gait Impairments | At 6 months | Differences in gait parameters in patients with a) AFDAS , (b) KAF and (c) NSR. |
| Cognitive Impairment | At 6 months | Differences in cognition in patients with (a) AFDAS , (b) KAF and (c) NSR |
| Frailty | At 6 months | Differences in frailty in patients with (a) AFDAS , (b) KAF and (c) NSR |
| Biomarkers | Within 48 hours of stroke onset, at 12, 30 and 90 days and at 6 months. | Differences in levels of plasma markers (BNP,endothelin-1, Lp(a), and TAFI) or neuroimaging/clinical predictors between patients with (a) AFDAS , (b) KAF and (c) NSR |
| Atrial Fibrillation Burden | At 14 days | Difference in atrial fibrillation burden (sum of atrial fibrillation episodes for a period of time) of AFDAS subjects with mild stroke/TIA compared to AFDAS subjects with moderate/severe stroke. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Stroke Recurrence | At 90, 180, and 360 days | Number of stroke recurrences in patients with (a) AFDAS , (b) KAF and (c) NSR |
| Death | At 90, 180, and 360 days | Number of deaths in (a) AFDAS , (b) KAF and (c) NSR groups |
Countries
Canada
Outcome results
None listed